Five biotech companies raised over $1.6 billion in a single week, headlined by Parabilis Medicines' record-shattering $670M IPO. The blockbuster stretch signals that public markets are genuinely back for biotech, but only for companies that bring real clinical data to the table.
A String of Blockbuster Biotech IPOs
Somewhere around 2023, biotech founders stopped dreaming about IPOs. The window was shut. Investors weren't picking up the phone. Going public felt about as realistic as getting a dinner reservation at Dorsia.
Then came 2026, and the floodgates didn't just crack open; they blew off the hinges.
A series of major biotech IPOs have defined the year so far: Parabilis Medicines ($670M), Eikon Therapeutics ($381M), Veradermics ($256M), Agomab Therapeutics ($200M), and SpyGlass Pharma ($150M). That's roughly $1.66 billion in fresh public capital for drug developers. It's the kind of momentum that makes venture capitalists text each other the champagne emoji.
But this isn't just a feel-good story about money sloshing around. The composition of these deals tells you something important about where biotech is headed.
The Record-Breaker: Parabilis Goes Massive
Parabilis Medicines (formerly FogPharma) didn't just go public. It set a record. The oncology company priced 33.5 million shares at $20 apiece, above its expected $17–$19 range, raising $670 million before fees. That makes it the largest venture-backed biotech IPO in history, dethroning obesity darling Kailera Therapeutics, which had raised $625 million just two months earlier in April.
And Parabilis wasn't done. Regeneron bought another $75 million in a concurrent private placement at $18 per share, tied to a research collaboration around Parabilis's core technology. All told, the company pulled in roughly $745 million in a single transaction.
What's the science? Parabilis develops "Helicon" peptides designed to hit intracellular protein targets that traditional drugs can't reach. Think of the proteome (all the proteins in your cells) as a giant apartment building. Most drugs can only knock on doors facing the street. Helicons can get inside and reach the apartments nobody else can access. Their lead drug, zolucatetide, targets a key node in the Wnt signaling pathway, a notorious driver of tumor growth.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Leerink Partners, BofA Securities, Evercore ISI, and Guggenheim Securities ran the books. The underwriters also have a 30-day option to buy 5,025,000 additional shares, which could tack on another $100 million.
Eikon: Nobel Prizes Meet Wall Street
Eikon Therapeutics raised $381 million in its February 2026 IPO by selling about 21.2 million shares at $18, the top of its range. The company landed on the Nasdaq under the ticker EIKN with a valuation just under $1 billion, a notable haircut from its $1.85 billion private valuation in 2025.
Eikon's origin story is genuinely cool. The company built its discovery engine on Nobel Prize-winning super-resolution microscopy, tracking individual protein molecules in real time inside living cells. Imagine watching a single car navigate rush-hour traffic from a helicopter, except the "car" is a protein and the "traffic" is the chaos inside a human cell.
But Eikon isn't just a platform play anymore. It has four clinical-stage programs, led by EIK-1001, an immune activator being tested alongside Merck's Keytruda in a 740-patient Phase 2/3 melanoma trial. An interim readout is expected in the second half of 2026. The pipeline also includes next-generation PARP inhibitors for ovarian and breast cancer and a brain-penetrant version targeting tumors that have spread to the central nervous system.
The Rest of the Pack: Hair Loss, Crohn's, and Eyedrops You Never Have to Use
Veradermics (NYSE: MANE) might have had one of the year's best debut stories. The company priced its February 2026 IPO at $17 per share, above its $14–$16 range, raising $256 million. Then it opened trading at $34 and closed at $37.75, a 122% pop on day one. Their pitch? An extended-release oral minoxidil pill for hair loss. Minoxidil has been around forever as a topical treatment (hello, Rogaine), but Veradermics is betting that a convenient once-daily pill with a controlled-release profile can capture a massive consumer market. They have three late-stage trials running, including a completed 519-patient Phase 2/3 study with data expected soon.
Agomab Therapeutics (Nasdaq: AGMB) raised $200 million in its February 2026 IPO to fund its oral drug ontunisertib, which blocks a protein called ALK5 involved in tissue scarring. Their lead target: fibrostenosing Crohn's disease, a severe form of Crohn's where scar tissue narrows the intestine. A global Phase 2b trial is the next big milestone.
SpyGlass Pharma (Nasdaq: SGP) brought in $150 million in its February 2026 IPO for its drug-eluting intraocular lens, essentially an implant that slowly releases glaucoma medication inside the eye. If it works, patients could skip daily eye drops entirely. Anyone who's ever tried to put drops in their own eyes (and missed) understands the appeal.
This Isn't 2021 All Over Again
It's tempting to look at these numbers and think we're back to the anything-goes frenzy of 2021, when 87+ biotechs went public and the sector raised roughly $16 billion in IPOs. We're not there. Not even close.
But that's actually the point. This recovery is built differently.
In 2021, preclinical companies with a slide deck and a dream could go public. In 2026, the market is demanding proof. PitchBook analyst Ben Zercher described it as a "bifurcated reopening," where "product-focused companies built around clinically grounded programs are forming the backbone of the window." Craig Hilts of Sidley Austin put it more simply: "The tide is turning," pointing to a string of upsized offerings as evidence that investor confidence has genuinely returned.
The numbers back this up. Biopharma companies raised $1.7 billion in Q1 2026 alone, the strongest quarter since 2021. The median biotech IPO size in 2026 is around $287.5 million, more than double 2025 levels. Analysts project 30 to 35 biotech IPOs for the full year if markets cooperate.
Why the Window Opened (and Whether It Stays Open)
Several forces converged to make this possible. The XBI biotech index climbed about 36% in 2025, delivering its best annual performance since 2021 and signaling that risk appetite was returning. A wave of Big Pharma M&A recycled billions back into the ecosystem, as companies facing patent cliffs went shopping for late-stage assets. And a more constructive interest-rate backdrop removed one of the biggest headwinds that had kept investors on the sidelines.
Crossover investors (the funds that buy into private rounds before an IPO, then hold through the listing) are back, but with tighter standards. They want late-stage data, near-term catalysts, and enough cash runway to reach meaningful milestones without needing another raise.
The result is a market that rewards the right kind of company generously while leaving weaker stories out in the cold. Venture capital is following the same pattern: mega-rounds of $100 million or more now account for roughly 60–75% of all dollars deployed in biotech, as investors concentrate bets on their highest-conviction picks.
The Bottom Line
One strong IPO stretch doesn't guarantee the party continues. Analysts are quick to note that this recovery still depends on macro stability, and an unexpected rate shock or policy curveball could slam the window shut again.
But the structure of these deals suggests something more durable than a sugar rush. Every one of these companies had clinical-stage programs, clear regulatory strategies, and specific near-term milestones. That's not speculation. That's investors making calculated bets on drugs they believe can work.
Biotech's public markets aren't just open. For the companies that show up with real data, they're rolling out the red carpet.
Clinical & Regulatory
5 min read
Prostate Cancer Just Got Its HER2 Moment
The FDA just approved the first targeted therapy for a specific genetic subtype of prostate cancer, turning PTEN loss from a bad prognosis into an actionable target. It's the same precision oncology playbook that transformed breast cancer, and it could reshape how we treat the most common male cancer.
